文献速递儿童血液肿瘤与免疫

儿童青少年癌症幸存者治疗后早期处方药使用情况

Early Post-Therapy Prescription Drug Usage among Childhood and Adolescent Cancer Survivors.
PubMed 文献 · J Pediatr · 2018-02-12

结果显示幸存者在治疗后早期多种药物类别处方使用率更高,包括阿片类、精神活性药物、激素及心血管药物,提示其医疗疾病负担更重。

要点

  • 幸存者阿片类药物处方风险为无癌症匹配个体的1.5至4.5倍。
  • 白血病、淋巴瘤、中枢神经系统及骨肿瘤幸存者抗抑郁药风险为2至5倍,抗焦虑药为3至7倍。
  • 治疗结束后第3年,白血病、淋巴瘤及骨肿瘤幸存者ACE抑制剂使用风险为3至13倍。

核心结论

  • 与无癌症史的匹配同龄人相比,儿童癌症幸存者在治疗后早期多种药物类别的处方使用率更高,提示医疗疾病负担更重。

主要发现

  • 幸存者填写阿片类处方的风险为无癌症匹配个体的1.5至4.5倍。
  • 白血病、淋巴瘤、中枢神经系统及骨肿瘤幸存者抗抑郁药使用风险为2至5倍,抗焦虑药使用风险为3至7倍。
  • 治疗结束后第3年,白血病、淋巴瘤及骨肿瘤幸存者血管紧张素转换酶抑制剂使用风险为3至13倍。
  • 幸存者更常使用阿片类、精神活性、激素及心血管药物。

临床怎么用

  • 所有普通儿科医生及专科医生应了解癌症幸存者治疗后早期可能出现的疾病负担,以指导基于风险的监测和生存期照护。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To describe the patterns of prescription drug use among child and adolescent survivors of cancer in the early post-therapy period compared with matched peers without a cancer history. STUDY DESIGN: Using the MarketScan commercial insurance claims database, we performed a retrospective cohort study identifying survivors of pediatric (0-21 years of age at diagnosis) leukemia, lymphoma, central nervous system, bone, or gonadal cancers who completed therapy from 2000 to 2011 and remained insured for 3 years post-therapy. Prescription fills during the first 3 years post-therapy were examined, categorized by drug class, and compared with age-, sex-, and region-matched individuals without cancer. RESULTS: We identified 1414 survivors and 14 007 comparators. Compared with those without cancer, survivors had 1.5-4.5 times greater risk for filling opioids. Survivors of leukemia, lymphoma, central nervous system, and bone cancers had 2-5 times the risk for antidepressant and 3-7 times the risk for anxiolytic use. Survivors of leukemia, lymphoma, and bone tumors had 3-13 times the risk for angiotensin-converting enzyme inhibitors by the third year post-therapy. CONCLUSION: Compared with peers without cancer, survivors of childhood cancer have greater rates of prescription use across many drug classes, suggesting greater medical morbidity. Survivors were more likely to use opioid, psychoactive, hormone, and cardiovascular medications. All general pediatricians and subspecialists should be aware of potentially emerging morbidities during the early post-therapy period to guide risk-based surveillance and survivorship care.

来源:J Pediatr,查看原文。版权归原作者所有。

引用

  1. Smitherman AB, Mohabir D, Wilkins TM, et al. Early Post-Therapy Prescription Drug Usage among Childhood and Adolescent Cancer Survivors. J Pediatr. 2018. PMID: 29395178. doi:10.1016/j.jpeds.2017.11.063

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。